Table 2.

Distribution of CDKN2A, IDH, ATRX, TP53 and 1p19q status by pathologic diagnosis in tumors from glioma patients in the UCSF Adult Glioma Study

	All cases		Diffuse astrocytoma (A-II)		Anaplastic astrocytoma (A-III)		Oligodendroglioma (O-II)		Anaplastic oligodendroglioma (O-III)		Oligoastrocytoma (OA-II)		Anaplastic oligoastrocytoma (OA-III)
	N	Percent	N	Percent	N	Percent	N	Percent	N	Percent	N	Percent	N	Percent
CDKN2A
Intact	159	63%	26	55%	30	49%	57	77%	16	73%	25	63%	5	56%
Deleted	94	37%	21	45%	31	51%	17	23%	6	27%	15	38%	4	44%
Total	253		47		61		74		22		40		9
IDH
Wild type	65	24%	10	21%	26	41%	9	11%	8	33%	8	19%	4	36%
Mutated	202	76%	37	79%	37	59%	71	89%	16	67%	34	81%	7	64%
Total	267		47		63		80		24		42		11
ATRX
Intact	156	60%	22	47%	24	39%	68	86%	20	87%	18	44%	4	36%
Lost	106	40%	25	53%	37	61%	11	14%	3	13%	23	56%	7	64%
Total	262		47		61		79		23		41		11
TP53
Wild type	107	63%	9	31%	24	48%	42	89%	14	82%	13	65%	5	63%
Mutated	64	37%	20	69%	26	52%	5	11%	3	18%	7	35%	3	38%
Total	171		29		50		47		17		20		8
1p19q
Intact	65	42%	NA*		NA*		19	25%	5	23%	29	74%	8	89%
Codeleted	89	58%					58	75%	17	77%	10	26%	1	11%
Total	154						77		22		39		9

^*NA, 1p19q data not available for tumors classified histologically as astrocytoma.